Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: Guidelines abound, but where are the data?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2015, Pages 144-156

  Azarbal, Amir ^a   Clavijo, Leonardo ^b   Gaglia, Michael A ^b  

^a UNIVERSITY OF ALABAMA IN HUNTSVILLE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

antiplatelet therapy; aspirin; clopidogrel; critical limb ischemia; peripheral arterial disease heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; PRASUGREL; PROSTANOID; RIVAROXABAN; TICAGRELOR; TICLOPIDINE; VORAPAXAR; PROSTAGLANDIN; TETRAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; BYPASS SURGERY; CRITICAL LIMB ISCHEMIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; GRAFT PATENCY; HUMAN; LEG REVASCULARIZATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ISCHEMIA; LIMB; PERIPHERAL ARTERIAL DISEASE; VASCULARIZATION;

ASPIRIN; DIPYRIDAMOLE; ENDOVASCULAR PROCEDURES; EXTREMITIES; HUMANS; ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTAGLANDINS; TETRAZOLES;

EID: 84922676567     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414545126     Document Type: Review

References (73)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with PAD (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. Circulation. 2006 ; 113 (11). e463 - e654
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007 ; 45 (suppl s). S5 - S67
3. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national health and nutrition examination survey, 1999-2000. Circulation. 2004 ; 110 (6). 738-743
4. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 ; 286 (11). 1317-1324
5. Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the reduction of atherothrombosis for continued health (REACH) registry. Atherosclerosis. 2009 ; 204: e86 - e92
6. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2013 ; 127 (14). 1522 1529e1521-1529 1526
7. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999 ; 47 (10). 1255-1256
8. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992 ; 326 (6). 381-386
9. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Vasc Med. 2011 ; 16 (6). 452-476
10. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (2 suppl). e669S - 690S
11. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32 (22). 2851-2906
12. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 (7329). 71-86
13. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373 (9678). 1849-1860
14. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009 ; 301 (18). 1909-1919
15. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010 ; 303 (18). 841-848
16. The RISC group. Lancet. 1990 ; 336 (8719). 827-830
17. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 ; 376 (9748). 1233-1243
18. Ranke C, Creutzig A, Luska G, et al. Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Investig. 1994 ; 72 (9). 673-680
19. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990 ; 41 (4). 263-269
20. Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation. 1995 ; 91 (8). 2167-2173
21. Weichert W, Meents H, Abt K, et al. Acetylsalicylic acid - reocclusion - prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. VASA. 1994 ; 23 (1). 57-65
22. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012 ; 8: Cd002071
23. Bernlochner I, Sibbing D. Thienopyridines and other ADP-receptor antagonists. Handb Exp Pharmacol. 2012 ; (210). 165-198
24. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 ; 5 (7). 1545-1551
25. CAPRIE steering committee. Lancet. 1996 ; 348 (9038). 1329-1339
26. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354 (16). 1706-1717
27. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009 ; 30 (2). 192-201
28. Shigematsu H, Komori K, Tanemoto K, Harada Y, Nakamura M. Clopidogrel for atherothrombotic event management in patients with peripheral arterial disease (COOPER) study: safety and efficacy of clopidogrel versus ticlopidine in Japanese patients. Ann Vasc Dis. 2012 ; 5 (3). 364-375
29. Linnemann B, Schwonberg J, Toennes SW, Mani H, Lindhoff-Last E. Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis. 2010 ; 209 (2). 504-509
30. Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010 ; 52 (4). 825 e821-833 822
31. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011 ; 112 (2). 292-318
32. Kohler TR, Kaufman JL, Kacoyanis G, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery. 1984 ; 96 (3). 462-466
33. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 1991 ; 13 (1). 150-161
34. Clyne CA, Archer TJ, Atuhaire LK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg. 1987 ; 74 (4). 246-248
35. Goldman MD, Simpson D, Hawker RJ, Norcott HC, McCollum CN. Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man. Ann Surg. 1983 ; 198 (6). 713-716
36. Kester RC. The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs. Ann R Coll Surg Engl. 1984 ; 66 (4). 241-246
37. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 1982 ; 92 (6). 1016-1026
38. Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2008 ; (4). Cd000535
39. Becker F, Robert-Ebadi H, Ricco JB, et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011 ; 42: S4 - S12
40. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. VASA. 2004 ; 33 (3). 137-144
41. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2010 ; (1). Cd006544
42. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005 ; 6 (4). 3-11
43. Han SW, Lee SS, Kim SH, et al. Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. Eur Neurol. 2013 ; 69 (1). 33-40
44. Weber T, Meyer F, Weber M, Halloul Z. [Role of cilostazol in the sequential therapeutic spectrum of the peripheral arterial occlusion disease (PAOD)]. Dtsch Med Wochenschr. 2012 ; 137 (20). 1051-1055
45. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 ; (1). Cd003748
46. Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002 ; 36 (2). 83-91
47. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012 ; 79 (4). 541-548
48. Miyashita Y, Saito S, Miyamoto A, Iida O, Nanto S. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology. 2011 ; 62 (1). 15-17
49. Study group on pharmacological treatment after PTA. Eur J Vasc Surg. 1994 ; 8 (1). 83-88
50. Mazur P, Frolow M, Nizankowski R, Sadowski J, Undas A. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets. 2013 ; 24 (2). 151-155
51. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007 ; 3 (2). 229-234
52. Serrano Hernando FJ, Martin Conejero A.. [Peripheral artery disease: pathophysiology, diagnosis and treatment]. Rev Esp Cardiol. 2007 ; 60 (9). 969-982
53. Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol. 2010 ; 55 (15). 1580-1589
54. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011 ; 4 (5). 495-504
55. Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012 ; 60 (7). 587-591
56. Burdess A, Nimmo AF, Garden OJ, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg. 2010 ; 252 (1). 37-42
57. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005 ; 42 (3). 456-464
58. Poredos P, Jezovnik MK. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?. VASA. 2013 ; 42 (2). 88-95
59. Drouet L, Bal dit Sollier C, Henry P.. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. Drugs. 2010 ; 70: 9-14
60. Elsayed S, Shavelle DM, Matthews RV, Clavijo LC. Resistance or high on-treatment platelet reactivity to aspirin and clopidogrel in patients with critical limb ischemia. J Am Coll Cardiol. 2012 ; 59: E2114 - E2114
61. Davis EM, Knezevich JT, Teply RM. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clin Pharmacol. 2013 ; 5: 67-83
62. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010 ; 121 (10). 1188-1199
63. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 ; 361 (11). 1045-1057
64. Patel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared to clopidogrel: data from the PLATO trial. Circulation. 2011 ; 124 (24). A14299
65. A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID). http://clinicaltrials.gov/show/NCT01732822. Accessed February 7, 2014.
66. Gaglia MA, Manoukian SV, Waksman R. Novel antiplatelet therapy. Am Heart J. 2010 ; 160 (4). 595-604
67. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 ; 366 (15). 1404-1413
68. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 ; 366 (1). 9-19
69. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 ; 363 (26). 2499-2510
70. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 ; 366 (14). 1287-1297
71. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 (10). 883-891
72. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007 ; 357 (3). 217-227
73. Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). http://www.clinicaltrials.gov/show/NCT01776424. Accessed June 2, 2014.